Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

202 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
CART19-BE-01: A Multicenter Trial of ARI-0001 Cell Therapy in Patients with CD19+ Relapsed/Refractory Malignancies.
Ortíz-Maldonado V, Rives S, Castellà M, Alonso-Saladrigues A, Benítez-Ribas D, Caballero-Baños M, Baumann T, Cid J, Garcia-Rey E, Llanos C, Torrebadell M, Villamor N, Giné E, Díaz-Beyá M, Guardia L, Montoro M, Català A, Faura A, González EA, Español-Rego M, Klein-González N, Alsina L, Castro P, Jordan I, Fernández S, Ramos F, Suñé G, Perpiñá U, Canals JM, Lozano M, Trias E, Scalise A, Varea S, Sáez-Peñataro J, Torres F, Calvo G, Esteve J, Urbano-Ispizua Á, Juan M, Delgado J. Ortíz-Maldonado V, et al. Among authors: calvo g. Mol Ther. 2021 Feb 3;29(2):636-644. doi: 10.1016/j.ymthe.2020.09.027. Epub 2020 Sep 20. Mol Ther. 2021. PMID: 33010231 Free PMC article. Clinical Trial.
First report of CART treatment in AL amyloidosis and relapsed/refractory multiple myeloma.
Oliver-Caldes A, Jiménez R, Español-Rego M, Cibeira MT, Ortiz-Maldonado V, Quintana LF, Castillo P, Guijarro F, Tovar N, Montoro M, Benitez-Ribas D, Bataller A, González-Navarro EA, Cid J, Lozano M, Perez-Amill L, Martin-Antonio B, Mena MP, Moreno DF, Rodríguez-Lobato LG, Campistol JM, Calvo G, Bladé J, Rosiñol L, Juan M, Pascal M, Urbano-Ispizua A, Fernández de Larrea C. Oliver-Caldes A, et al. Among authors: calvo g. J Immunother Cancer. 2021 Dec;9(12):e003783. doi: 10.1136/jitc-2021-003783. J Immunother Cancer. 2021. PMID: 34876408 Free PMC article.
Factors associated with the clinical outcome of patients with relapsed/refractory CD19+ acute lymphoblastic leukemia treated with ARI-0001 CART19-cell therapy.
Ortiz-Maldonado V, Rives S, Español-Rego M, Alonso-Saladrigues A, Montoro M, Magnano L, Giné E, Pascal M, Díaz-Beyá M, Castella M, Català A, Faura A, Rodríguez-Lobato LG, Oliver-Caldes A, Martínez-Roca A, Rovira M, González-Navarro EA, Ortega JR, Cid J, Lozano M, Garcia-Rey E, Fernández S, Castro P, Jordan I, Villamor N, Aymerich M, Torrebadell M, Deyà À, Fernández de Larrea C, Benitez-Ribas D, Trias E, Varea S, Calvo G, Esteve J, Urbano-Ispizua A, Juan M, Delgado J. Ortiz-Maldonado V, et al. Among authors: calvo g. J Immunother Cancer. 2021 Dec;9(12):e003644. doi: 10.1136/jitc-2021-003644. J Immunother Cancer. 2021. PMID: 34907029 Free PMC article. No abstract available.
Tolerability and Reactogenicity Profile of mRNA SARS-Cov-2 Vaccines from a Mass Vaccination Campaign in a Tertiary Hospital: Between-Vaccine and Between-Population Prospective Observational Study (VigilVacCOVID Study).
Sáez-Peñataro J, Torres F, Bartra J, Bascuas J, Vilella A, Tortajada M, Quesada S, González E, López-Suñé E, Castells A, Serrano S, Camacho C, Trilla A, Calvo G; VigilVacCOVID Group. Sáez-Peñataro J, et al. Among authors: calvo g. BioDrugs. 2022 Jul;36(4):509-520. doi: 10.1007/s40259-022-00543-9. Epub 2022 Jun 28. BioDrugs. 2022. PMID: 35764768 Free PMC article.
Nitrendipine and enalapril combination therapy in mild to moderate hypertension: assessment of dose-response relationship by a clinical trial of factorial design.
Roca-Cusachs A, Torres F, Horas M, Ríos J, Calvo G, Delgadillo J, Terán M; Spanish Nitrendipine/Enalapril Collaborative Study Group. Roca-Cusachs A, et al. Among authors: calvo g. J Cardiovasc Pharmacol. 2001 Dec;38(6):840-9. doi: 10.1097/00005344-200112000-00005. J Cardiovasc Pharmacol. 2001. PMID: 11707687 Clinical Trial.
Efficacy of rituximab in 164 patients with biopsy-proven lupus nephritis: pooled data from European cohorts.
Díaz-Lagares C, Croca S, Sangle S, Vital EM, Catapano F, Martínez-Berriotxoa A, García-Hernández F, Callejas-Rubio JL, Rascón J, D'Cruz D, Jayne D, Ruiz-Irastorza G, Emery P, Isenberg D, Ramos-Casals M, Khamashta MA; UK-BIOGEAS Registry. Díaz-Lagares C, et al. Autoimmun Rev. 2012 Mar;11(5):357-64. doi: 10.1016/j.autrev.2011.10.009. Epub 2011 Oct 18. Autoimmun Rev. 2012. PMID: 22032879
Rates of, and risk factors for, severe infections in patients with systemic autoimmune diseases receiving biological agents off-label.
Díaz-Lagares C, Pérez-Alvarez R, García-Hernández FJ, Ayala-Gutiérrez MM, Callejas JL, Martínez-Berriotxoa A, Rascón J, Caminal-Montero L, Selva-O'Callaghan A, Oristrell J, Hidalgo C, Gómez-de-la-Torre R, Sáez L, Canora-Lebrato J, Camps MT, Ortego-Centeno N, Castillo-Palma MJ, Ramos-Casals M; BIOGEAS Study Group. Díaz-Lagares C, et al. Arthritis Res Ther. 2011 Jul 11;13(4):R112. doi: 10.1186/ar3397. Arthritis Res Ther. 2011. PMID: 21745378 Free PMC article.
202 results